---
document_datetime: 2024-05-24 16:54:00
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tenofovir-disoproxil-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: tenofovir-disoproxil-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.2734866
conversion_datetime: 2025-12-30 09:55:36.087399
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tenofovir disoproxil Zentiva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0031              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 22/05/2024                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0030/G   | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an   | 05/01/2024   | n/a        |                   | ASMF   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|--------|
| IB/0029     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                       | 03/07/2023   | 04/08/2023 | SmPC and PL       |        |
| IB/0028     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                       | 15/09/2022   | 04/08/2023 | SmPC and Annex II |        |
| IA/0027     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                       | 09/06/2022   | n/a        |                   |        |

<div style=\"page-break-after: always\"></div>

| N/0026             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                    | 17/03/2022   | 04/08/2023   | PL                               |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0025            | B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation                                                                                                                                                                                                              | 23/11/2021   | n/a          |                                  |                                                                                                                                           |
| IB/0024/G          | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits | 20/10/2021   | n/a          |                                  |                                                                                                                                           |
| R/0023             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                             | 20/05/2021   | 16/07/2021   | Annex II and Labelling           |                                                                                                                                           |
| IB/0022            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                        | 28/01/2021   | 16/07/2021   | SmPC, Annex II, Labelling and PL |                                                                                                                                           |
| PSUSA/2892/ 202003 | Periodic Safety Update EU Single assessment - tenofovir disoproxil                                                                                                                                                                                                                                                                                  | 12/11/2020   | 14/01/2021   | SmPC, Annex II, Labelling and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2892/202003. |
| PSUSA/2892/ 201903 | Periodic Safety Update EU Single assessment - tenofovir disoproxil                                                                                                                                                                                                                                                                                  | 14/11/2019   | 13/01/2020   | SmPC                             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                    |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       | PSUSA/2892/201903.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------|
| IB/0020   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                  | 29/08/2019 | 16/09/2019 | SmPC and PL           |                      |
| IB/0017/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                   | 06/07/2019 | n/a        |                       |                      |
| IB/0018/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 23/05/2019 | 16/09/2019 | SmPC, Annex II and PL |                      |

<div style=\"page-break-after: always\"></div>

| IA/0016     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                            | 29/04/2019   | n/a        |             |                                   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------|
| IAIN/0015   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                 | 12/03/2019   | n/a        |             |                                   |
| IB/0014/G   | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 19/02/2019   | 16/09/2019 | SmPC and PL |                                   |
| IB/0013     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                  | 07/02/2019   | n/a        |             |                                   |
| IG/1029     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                               | 18/12/2018   | n/a        |             |                                   |
| PSUSA/2892/ | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                  | 31/10/2018   | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| 201803      | tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                 |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IA/0011     | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                    | 13/09/2018 | n/a        |                 |
| IB/0009     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                   | 03/09/2018 | n/a        |                 |
| IAIN/0008/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 18/05/2018 | 07/12/2018 | Annex II and PL |
| IB/0007/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO                                                                                                                                                                                                                                            | 18/01/2018 | 07/12/2018 | SmPC and PL     |

<div style=\"page-break-after: always\"></div>

|                    | the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                     |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------|
| PSUSA/2892/ 201703 | Periodic Safety Update EU Single assessment - tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 26/10/2017 | n/a        |                     | PRAC Recommendation - maintenance |
| II/0001            | B.I.z - Update of Tenofovir disoproxil phosphate DMF no. EU/ASMF/00052 with the addition of a new intermediate active substance manufacturer. B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                           | 27/04/2017 | n/a        |                     |                                   |
| IB/0004            | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                           | 20/04/2017 | 18/01/2018 | SmPC                |                                   |
| IB/0003            | B.II.e.5.z - Change in pack size of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/02/2017 | 18/01/2018 | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                            |            |            | PL                     |                                                                                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0002/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following change for the reference | 27/01/2017 | 18/01/2018 | SmPC, Labelling and PL | assessment of the same product - Implementation of new additional data is required the MAH C.I.2.a - Change in the SPC, generic/hybrid/biosimilar products assessment of the same change product - Implementation of new additional data is required the MAH |